Skip to main content
Clinical Trials/NCT02567032
NCT02567032
Completed
Early Phase 1

Mechanisms and Effects of Oxytocin on Social Cognition in Schizophrenia - Behavioral

University of California, San Francisco2 sites in 1 country324 target enrollmentOctober 2010

Overview

Phase
Early Phase 1
Intervention
Oxytocin
Conditions
Schizophrenia
Sponsor
University of California, San Francisco
Enrollment
324
Locations
2
Primary Endpoint
Change in Social Cognition Task Performance
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

In this study, investigators will examine the behavioral effects and neurophysiological mechanisms of the pro-social neuropeptide oxytocin in patients with recent-onset schizophrenia and other psychotic disorders. Such research is a necessary first step towards identifying whether intranasal oxytocin administration can serve as an adjunct treatment for social impairments in schizophrenia and other psychotic disorders.

Aim 1: To quantify the effects of exogenous oxytocin on social cognition and behavior in patients with recent-onset schizophrenia.

Hypothesis A: Patients and healthy comparison subjects will show enhanced social cognition (e.g., improved interpretation of paralinguistic and emotional cues, such as those involved in emotional or sarcastic communication) after administration of oxytocin versus placebo.

Hypothesis B: Patients and healthy comparison subjects will show increased attention to others' eyes and patients will exhibit increased facial affect expressivity after administration of oxytocin versus placebo.

Detailed Description

Part 2: A supplementary study will be added to the proposed parent study, which includes additional behavioral testing consisting of several social cognition computer tasks, clinical assessments, physiological measurements, and questionnaires. The study will be conducted with the same study arms and study interventions as in the proposed parent study. For this supplementary study, the inclusion criteria has broadened to include patients with bipolar disorder with psychotic features and brief psychotic disorder.

Registry
clinicaltrials.gov
Start Date
October 2010
End Date
August 2019
Last Updated
6 years ago
Study Type
Interventional
Study Design
Crossover
Sex
Male

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Joshua Woolley

Principal Investigator

University of California, San Francisco

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

Oxytocin

40 IU Oxytocin

Intervention: Oxytocin

Saline Nasal Spray

Placebo Comparator

Intervention: Saline Nasal Spray

Outcomes

Primary Outcomes

Change in Social Cognition Task Performance

Time Frame: Through study completion, 2-3 weeks

Participants will undergo computer tasks that measure social cognition. Tasks will involve verbal responses, pressing buttons at specific times, listening, and viewing audio-visual stimuli. Investigators will be measuring the difference in accuracy and verbal content of the responses on the oxytocin day compared to the placebo day.

Secondary Outcomes

  • Physiological Measurements(Through study completion, 2-3 weeks)
  • Questionnaire(At baseline visit, up to 4 hours)

Study Sites (2)

Loading locations...

Similar Trials